AstraZeneca Withdraws COVID-19 Vaccine Amid TTS Concerns

AstraZeneca, the British-Swedish pharmaceutical company, announced the global withdrawal of its COVID-19 vaccine on May 7, 2024, citing an abundance of newer vaccines targeting emerging variants. This withdrawal, however, coincides with the revelation of court documents in the UK acknowledging a rare side effect with the vaccine: Thrombosis with Thrombocytopenia Syndrome (TTS).

While AstraZeneca attributes the withdrawal of the vaccine from the market to declining demand, it is worth considering that the vaccine has been linked to 51 cases of deaths and serious injuries attributed to TTS, according to the Telegraph. This revelation raises critical questions about vaccine safety and regulatory oversight, which may serve as a significant factor prompting victims and bereaved families to seek damages totaling approximately US$125 million. 

TTS is characterized by blood clot formation alongside low platelet counts, presenting significant health risks. According to the Australian Government Department of Health and Aged Care, symptoms of vaccine-induced thrombotic thrombocytopenia (VITT) typically manifested between four and 42 days after the first dose, primarily as severe headaches, abdominal pain, leg swelling, shortness of breath, and neurological deficits. In Australia, TTS affected around 2 to 3 individuals per 100,000 vaccinated with AstraZeneca. Consequently, the vaccine was banned in Australia on March 21, 2023, to prevent additional cases of AstraZeneca-related TTS. 

According to reports from Pharmaceutical Technology, in April 2021, the European Medicines Agency’s (EMA) safety committee and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) were cognizant of the vaccine's adverse effects. However, they determined that the benefits of the vaccine outweighed its potential risks, resulting in the administration of over three billion doses worldwide.

In Mexico, AstraZeneca received its initial authorization from Federal Commission for Protection against Sanitary Risk.(COFEPRIS) in January 2021. By June 2022, the company had supplied the country with the highest number of confirmed doses, totaling 79.43 million out of 204.83 million doses.

Despite the withdrawal of the AstraZeneca vaccine, the revelation of the risk of Thrombosis with Thrombocytopenia Syndrome (TTS) has raised concerns among vaccine recipients. This has prompted the WHO to issue emergency guidance to enhance awareness and assist healthcare providers in managing potential TTS cases.